---
title: Patient-reported outcomes in high-risk HR+Â /HER2- early breast cancer patients
  treated with endocrine therapy with or without palbociclib within the randomized
  PENELOPE<sup>B</sup> study
date: '2023-11-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38000218/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231125170656&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Patient-reported global QoL and fatigue did not substantially
  change in both treatment arms. Slight differences in GHS, physical functioning,
  and fatigue favored the placebo arm statistically without achieving clinically meaningful
  ...'
disable_comments: true
---
CONCLUSION: Patient-reported global QoL and fatigue did not substantially change in both treatment arms. Slight differences in GHS, physical functioning, and fatigue favored the placebo arm statistically without achieving clinically meaningful ...